<p>Cardiol Therapeutics Inc. (TSE:CRDL - 获取免费报告) 的股价在周三上涨了 1.5%。该股票最高交易价为 1.37 加元，最后交易价为 1.37 加元。在交易过程中，共成交 34,206 股，较平均交易量 54,240 股下降了 37%。该股票此前收盘价为 1.35 加元。</p>
<p>获取 <strong>Cardiol Therapeutics</strong> 的提醒：</p>
<h2>Cardiol Therapeutics 股价上涨 1.5%</h2>
<p>该公司的市值为 1.37 亿加元，市盈率为-3.34，贝塔值为 1.68。公司的速动比率为 6.84，流动比率为 2.49，债务与股本比率为 1.59。该公司的 50 日简单移动平均线为 1.40 加元，200 日简单移动平均线为 1.56 加元。</p>
<p>Cardiol Therapeutics (TSE:CRDL - 获取免费报告) 最近在 11 月 13 日星期四发布了季度财报。公司报告该季度每股收益为 C($0.12)。整体来看，股票研究分析师预计 Cardiol Therapeutics Inc.在当前财政年度的每股收益将为-0.49。</p>
<h2>Cardiol Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL 是一家临床阶段的生命科学公司，专注于心脏病的抗炎和抗纤维化疗法的研究与临床开发。公司的主要药物候选者 CardiolRxTM（大麻二酚）口服溶液，经过药品制造，并正在进行临床开发以用于心脏病的治疗。已知大麻二酚可以抑制炎症小体通路的激活，这是一种已知在心肌炎、心包炎和心力衰竭相关的炎症和纤维化的发展与进展中发挥重要作用的细胞内过程。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cardiol Therapeutics</li>
<li>埃隆将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护你的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>用这四个简单步骤让你的银行账户 “防联储”</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Cardiol Therapeutics 吗？</h2>
<p>在你考虑 Cardiol Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cardiol Therapeutics 并不在名单上。</p>
<p>虽然 Cardiol Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRDL

<p>Cardiol Therapeutics (TSE:CRDL) 的股价上涨了 1.5%，达到 1.37 加元，成交量为 34,206 股，较平均成交量下降了 37%。该公司的市值为 1.37 亿加元，报告的季度每股亏损为 0.12 加元。分析师预计本财年的每股收益为-0.49。Cardiol 专注于开发心脏病治疗方案，其主要候选产品为 CardiolRxTM，一种大麻二酚溶液。尽管股价上涨，但在分析师中，该股票被评为持有评级，他们建议其他股票可能是更好的投资选择</p>

<p>Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s stock price shot up 1.5% on Wednesday . The stock traded as high as C$1.37 and last traded at C$1.37. 34,206 shares changed hands during trading, a decline of 37% from the average session volume of 54,240 shares. The stock had previously closed at C$1.35.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc. (TSE:CRDL - 获取免费报告) 的股价在周三上涨了 1.5%。该股票最高交易价为 1.37 加元，最后交易价为 1.37 加元。在交易过程中，共成交 34,206 股，较平均交易量 54,240 股下降了 37%。该股票此前收盘价为 1.35 加元。</p>
</div><p>Get <strong>Cardiol Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cardiol Therapeutics</strong> 的提醒：</p>
</div><h2>Cardiol Therapeutics Stock Up 1.5%</h2>
<div class="lb-trans"><h2>Cardiol Therapeutics 股价上涨 1.5%</h2>
</div><p>The company has a market cap of C$137.00 million, a PE ratio of -3.34 and a beta of 1.68. The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59. The firm's fifty day simple moving average is C$1.40 and its 200-day simple moving average is C$1.56.</p>
<div class="lb-trans"><p>该公司的市值为 1.37 亿加元，市盈率为-3.34，贝塔值为 1.68。公司的速动比率为 6.84，流动比率为 2.49，债务与股本比率为 1.59。该公司的 50 日简单移动平均线为 1.40 加元，200 日简单移动平均线为 1.56 加元。</p>
</div><p>Cardiol Therapeutics (TSE:CRDL - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. As a group, equities research analysts expect that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cardiol Therapeutics (TSE:CRDL - 获取免费报告) 最近在 11 月 13 日星期四发布了季度财报。公司报告该季度每股收益为 C($0.12)。整体来看，股票研究分析师预计 Cardiol Therapeutics Inc.在当前财政年度的每股收益将为-0.49。</p>
</div><h2>Cardiol Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cardiol Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Cardiol Therapeutics Inc NASDAQ: CRDLTSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.</p>
<div class="lb-trans"><p>Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL 是一家临床阶段的生命科学公司，专注于心脏病的抗炎和抗纤维化疗法的研究与临床开发。公司的主要药物候选者 CardiolRxTM（大麻二酚）口服溶液，经过药品制造，并正在进行临床开发以用于心脏病的治疗。已知大麻二酚可以抑制炎症小体通路的激活，这是一种已知在心肌炎、心包炎和心力衰竭相关的炎症和纤维化的发展与进展中发挥重要作用的细胞内过程。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Cardiol Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cardiol Therapeutics</li>
<li>埃隆将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护你的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>执行命令 14330：特朗普最大的一次</li>
<li>用这四个简单步骤让你的银行账户 “防联储”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cardiol Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Cardiol Therapeutics 吗？</h2>
</div><p>Before you consider Cardiol Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cardiol Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cardiol Therapeutics 并不在名单上。</p>
</div><p>While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cardiol Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cardiol Therapeutics (TSE:CRDL) 的股票价格上涨了 1.5% - 现在是否仍然值得购买？